



Docket No.: 025562.0012-US01

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Bradley P. Glassman et al.

Application No.: 10/756,354

Group Art Unit: 1615

Filed: January 14, 2004

Examiner: S. L. Howard

For: METHOD OF TREATING ONYCHOMYCOSIS

WITH UREA AND AN ANTIOXIDANT

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed are the following items for filing in connection with the above-referenced Patent Application:

- 1. Information Disclosure Statement;
- 2. Form PTO/SB/08a/b;
- 3. Eight cited documents; and
- 4. Return receipt postcard.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0740, under Docket No. 025562.0012-US01. A duplicate copy of this paper is enclosed.

Application No.: 10/756,354 2 Docket No.: 025562.0012-US01

It is not believed that extensions of time fees are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 50-0740.

Dated: December 29, 2004

Respectfully submitted,

Andrea G. Reister

Registration No.: 36,253 COVINGTON & BURLING 1201 Pennsylvania Avenue, N.W. Washington, DC 20004-2401

(202) 662-6000

Attorney for Applicant



Docket No.: 025562.0012-US01

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Bradley P. Glassman et al.

Application No.: 10/756,354

Group Art Unit: 1615

Filed: January 14, 2004

Examiner: S. L. Howard

For: METHOD OF TREATING ONYCHOMYCOSIS WITH UREA AND AN ANTIOXIDANT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08a/b are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO/SB/08a/b based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior

Application No.: 10/756,354 2 Docket No.: 025562.0012-US01

art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120, 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☑ 1. This Information Disclosure Statement is being filed within three months of the
 U.S. filing date OR before the mailing date of a first Office Action on the merits.
 No statement under 37 C.F.R. § 1.97(e) or fee is required.
- □ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - □ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

The Examiner's attention is directed to co-pending U.S. Patent Application No.

The identification of this U.S. Patent Application is not to be construed as a

, filed _____, which is directed to related technical subject matter.

appears below:

□ 7.

waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

□ 8. Copies of the documents were cited by or submitted to the Office in Application

No. _______, filed _______, which is relied upon for an earlier filing date

under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37

C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO/SB/08a/b, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0740, referencing Docket No. 025562.0012-US01.

Dated: December 29, 2004

Respectfully submitted,

Andrea G. Reister

Registration No.: 36,253 COVINGTON & BURLING

1201 Pennsylvania Avenue, N.W.

Washington, DC 20004-2401

(202) 662-6000

Attorney for Applicant

DEC 2 9 2004 LUNder the Palvesonk Reduction Act of 1992, no p

of

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

025562.0012-US01

Substitute for form 1449A/B/PA TRADELINE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/756,354-Conf. #3208

Filing Date January 14, 2004

First Named Inventor Bradley P. Glassman

Art Unit 1615

Examiner Name S. L. Howard

Attomey Docket Number

1

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Number-Kind Code ² (if known)						
	AA	US-4,721,724	01-26-1988	Stettendorf et al.				
	AB	US-5,346,692	09-13-1994	Wohlrab et al.				
	AC	US-5,696,164-B2	12-09-1997	Sun et al.				
	AD	US-US 2004/0033963-A1	02-19-2004	Yu et al.				
	AE	US-6,821,508-B2	11-23-2004	Zatz et al.				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]		
	BA	GB-2116425-A	09-28-1983	Rohm Pharma GmbH				
·	BB	EP-0 440 298-A1	08-07-1991	GIST-BROCADES N.V.				
	BC	WO-WO 01/17484-A2	03-15-2001	D.T.R. Dermal Therapy				
				Research Inc.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

Sheet

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.